Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALOMA: Amivantamab SC in Advanced Solid Malignancies
NCT04606381Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Jul 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of amivantamab in solid malignancy (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Observed Amivantamab Serum Concentration Immediately Prior to the Next Dose Administration at Day 29, Number of Participants with Adverse Event (AE) and 2 more. Started Nov 2020; status: active, not recruiting.
02
Drugs
amivantamab
03
Conditions
solid malignancy
Beyond the preview
Go deeper on NCT04606381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606381.